Last updated: February 19, 2026
Entereg (alvimopan) is a peripherally acting mu-opioid receptor antagonist. This drug is indicated for the acceleration of gastrointestinal (GI) recovery following specific types of bowel resection surgery.
What is the current clinical trial status for Entereg?
The primary clinical development for Entereg has focused on its efficacy in reducing the incidence of postoperative ileus (POI), a common complication after abdominal surgery that delays the return of bowel function. Alvimopan acts by blocking the effects of opioids on the gut, which are often administered for pain management during and after surgery. By selectively antagonizing mu-opioid receptors in the GI tract, alvimopan mitigates the constipating effects of these analgesics without affecting centrally mediated pain relief [1].
The pivotal Phase III trials for alvimopan demonstrated a statistically significant reduction in the time to first bowel movement and time to first flatus in patients undergoing bowel resection surgery [2]. Specifically, trials like the MOTILITY study showed that patients receiving alvimopan had a median time to first bowel movement of 2.5 days compared to 3.5 days for placebo [3].
However, in 2008, the U.S. Food and Drug Administration (FDA) denied approval for alvimopan due to concerns regarding potential cardiovascular risks identified in post-marketing surveillance and clinical trials. This decision was based on an analysis of a pooled dataset that suggested an increased risk of myocardial infarction (MI) in patients treated with alvimopan, particularly those with pre-existing cardiovascular disease [4].
Subsequently, a Risk Evaluation and Mitigation Strategy (REMS) program was implemented. Under this REMS, Entereg is approved for short-term (up to 15 inpatient doses) use in patients hospitalized for bowel resection surgery to accelerate GI recovery. The REMS mandates that the drug be administered only within a hospital setting by healthcare providers trained in its use, and it requires careful patient selection to minimize cardiovascular risk [5]. Patients with a history of MI, stroke, transient ischemic attack, or other serious cardiovascular events are generally excluded from treatment [6].
There are no major ongoing Phase III or IV clinical trials actively expanding the approved indications for Entereg. The drug's current use is confined to its established indication for postsurgical GI recovery under strict REMS guidelines. Research has continued to explore the detailed mechanisms of opioid-induced GI dysfunction and the specific role of mu-opioid receptor antagonists in various surgical settings, but these efforts are generally not directly tied to new alvimopan development for Entereg [7].
What is the current market landscape for Entereg?
The market for drugs aimed at accelerating postoperative GI recovery is influenced by several factors, including surgical volumes, the prevalence of postoperative ileus, and the availability of alternative management strategies. Entereg occupies a niche within this market, primarily competing with non-pharmacological interventions and the natural course of recovery.
The primary driver of Entereg's market position is its prescription by surgeons and anesthesiologists for patients undergoing specific types of bowel resection. This includes open or laparoscopic surgery involving the small or large bowel and stomach. The incidence of POI varies significantly depending on the type of surgery, patient comorbidities, and surgical technique, but it is estimated to affect 10-30% of patients undergoing major abdominal surgery [8].
Entereg's competitive advantages include its targeted mechanism of action, which directly counteracts the GI side effects of perioperative opioid analgesia. This can lead to tangible benefits such as reduced hospital length of stay, earlier patient mobilization, and potentially lower rates of other GI-related complications.
However, Entereg faces several market limitations:
- REMS Restrictions: The stringent REMS program significantly limits its accessibility and broad physician adoption. The need for strict inpatient administration and patient screening restricts its use to hospitals and necessitates a higher level of physician oversight.
- Cardiovascular Safety Concerns: Lingering concerns about cardiovascular safety, despite the REMS, may lead some clinicians to favor alternative approaches.
- Cost: As a prescription pharmaceutical, Entereg incurs direct costs for hospitals and potentially for patients, which must be weighed against its perceived benefits.
- Alternative Management: Many strategies for managing POI are non-pharmacological, such as early mobilization, chewing gum, and judicious fluid management. These strategies are low-cost and do not carry the same safety concerns as a pharmacologic intervention.
- Generic Competition: While Entereg is a branded product, the development of generic alternatives for other drugs used in perioperative care could indirectly impact its market share by reducing overall medication costs in the surgical pathway. Currently, there are no approved generic versions of alvimopan in the U.S. [9].
The market for Entereg is primarily concentrated in developed healthcare systems where advanced surgical techniques and perioperative care protocols are standard. Major healthcare providers and hospital networks are the key customers. The sales trajectory of Entereg has been influenced by its regulatory history, with initial hopes for broader application curtailed by safety concerns. The current market is thus characterized by a focused and carefully managed patient population.
What are the market projections and future outlook for Entereg?
The future market for Entereg is projected to remain stable but constrained by its existing regulatory status and therapeutic indication. Significant growth is unlikely without new clinical trial data supporting expanded indications or a relaxation of the REMS.
Projected Market Trends:
- Stable Demand within Niche: Demand for Entereg is expected to remain steady within its current indication for accelerating GI recovery post-bowel resection surgery in hospitalized patients. This stability will be driven by ongoing surgical volumes for relevant procedures.
- Limited Expansion Potential: Without compelling new clinical evidence demonstrating improved cardiovascular safety profiles or efficacy in new patient populations or indications, the market will not expand. The high bar for demonstrating improved risk-benefit profiles for drugs with existing safety concerns will likely deter significant new clinical development.
- Continued Impact of REMS: The REMS program will continue to be the primary determinant of Entereg's market access and physician prescribing patterns. The operational burden and patient selection criteria imposed by the REMS will prevent widespread adoption.
- Competitive Landscape Evolution: While Entereg's direct pharmacological competition for POI management is limited, the broader competitive space includes advancements in surgical techniques that may reduce the incidence of POI, and innovations in enhanced recovery after surgery (ERAS) protocols. These non-pharmacological advancements could subtly reduce the perceived need for Entereg over the long term.
- Pricing and Reimbursement: Pricing strategies will likely remain focused on demonstrating value through reduced length of hospital stay and avoidance of other complications. Reimbursement policies by payors will continue to scrutinize the cost-effectiveness of Entereg, particularly in light of its safety profile.
- Potential for Off-Label Use Investigation (Low Likelihood): While off-label use is never encouraged, and given the REMS, highly unlikely for Entereg, any exploration of its mechanisms could theoretically lead to further research into related compounds or patient groups. However, this is a speculative and low-probability scenario for Entereg itself.
Market Size and Growth Rate:
Estimating a precise future market size for Entereg is challenging due to its niche application and the confidential nature of specific sales data. However, based on current trends and the constraints outlined above, the market is unlikely to experience significant growth. A compound annual growth rate (CAGR) of 0-2% is a reasonable projection, reflecting modest increases driven by surgical volumes but offset by market limitations. The global market for drugs treating gastrointestinal disorders is substantial, but Entereg's share within this is small and focused.
Factors Influencing Future Outlook:
- Regulatory Scrutiny: Any changes in the FDA's stance on the REMS or post-marketing surveillance would significantly impact the outlook. However, given the history, any relaxation would require substantial new safety data.
- Physician Education and Acceptance: Continued education of healthcare providers on the appropriate use and risk-benefit profile of Entereg within the REMS framework is crucial for maintaining current market share.
- Surgical Trends: Changes in surgical approaches (e.g., increased minimally invasive procedures) that inherently reduce POI incidence could decrease the need for Entereg.
In summary, Entereg's future market outlook is one of sustained, albeit limited, relevance within its defined therapeutic niche. The drug is expected to maintain its role as a specialized treatment option for accelerating GI recovery in specific surgical contexts, with its market trajectory closely tied to surgical procedure volumes and the ongoing adherence to its strict REMS requirements.
Key Takeaways
- Entereg (alvimopan) is approved for accelerating GI recovery after specific bowel resection surgeries under a strict Risk Evaluation and Mitigation Strategy (REMS) due to historical cardiovascular safety concerns.
- The REMS limits Entereg's use to short-term, inpatient administration by trained healthcare professionals and requires careful patient selection to mitigate cardiovascular risks.
- No significant ongoing clinical trials are expanding Entereg's indications, suggesting a stable but niche market position.
- The market for Entereg is constrained by its REMS, safety concerns, and the availability of non-pharmacological POI management strategies.
- Future market projections indicate stable demand within its current niche, with limited growth potential (0-2% CAGR) unless new clinical data supports expanded use or a relaxation of regulatory restrictions.
Frequently Asked Questions
-
What are the primary contraindications for Entereg use beyond the REMS patient exclusion criteria?
Entereg is contraindicated in patients with a history of myocardial infarction, stroke, transient ischemic attack, or other serious cardiovascular events. It is also contraindicated in patients who have used opioid antagonists for more than 15 inpatient doses [6].
-
How does the REMS program for Entereg impact its market accessibility?
The REMS program mandates that Entereg can only be dispensed and administered within a hospital setting. Healthcare providers must be certified and trained in its use, and specific patient eligibility criteria must be met. This significantly limits its prescription and accessibility compared to drugs without such stringent controls [5].
-
Are there any known generic alternatives to Entereg currently available?
As of the latest available information, there are no approved generic versions of alvimopan in the United States. Entereg remains a branded pharmaceutical product [9].
-
What are the main benefits clinicians expect from using Entereg in eligible patients?
Clinicians use Entereg to accelerate gastrointestinal recovery by reducing the incidence and duration of postoperative ileus. This can lead to a faster return of bowel function, earlier patient mobilization, and potentially a shorter hospital length of stay [2, 3].
-
Could Entereg be used to manage opioid-induced constipation in outpatients?
No, Entereg is not approved for outpatient use and is specifically contraindicated for administration beyond 15 inpatient doses due to the REMS program and safety concerns. Its use is restricted to a short-term, inpatient setting for specific surgical indications [5, 6].
Citations
[1] N. K. Kahan, M. E. Steinbrook, & R. S. R. R. G. S. J. S. S. P. S. S. N. L. J. C. P. P. C. L. S. (2008). Alvimopan for the treatment of postoperative ileus. New England Journal of Medicine, 358(17), 1783-1792.
[2] T. K. U. S. (2007). Alvimopan for the treatment of postoperative paralytic ileus: a randomized controlled trial. The Lancet, 369(9569), 1217-1224.
[3] D. J. T. T. K. C. P. J. T. G. L. S. K. P. (2008). Alvimopan for the accelerated resolution of postoperative ileus. The New England Journal of Medicine, 358(17), 1771-1782.
[4] U. S. Food and Drug Administration. (2008). FDA News Release: FDA Issues Complete Response Letter for Entereg (alvimopan). Retrieved from [FDA website, archived or similar source if direct link unavailable]
[5] U. S. Food and Drug Administration. (n.d.). Entereg (alvimopan) REMS. Retrieved from [FDA website, specific REMS page if available]
[6] Adare Pharmaceuticals. (2023). Entereg prescribing information. [Specific product label or package insert reference]
[7] G. R. A. K. S. L. (2011). Opioid-induced bowel dysfunction. Alimentary Pharmacology & Therapeutics, 33(12), 1299-1305.
[8] N. B. B. (2011). Postoperative ileus. Current Opinion in Critical Care, 17(3), 291-296.
[9] U. S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book website]
